Albany Molecular Research, Inc. (NASDAQ:AMRI) Expected to Announce Earnings of $0.23 Per Share

Wall Street analysts forecast that Albany Molecular Research, Inc. (NASDAQ:AMRI) will announce earnings per share of $0.23 for the current quarter, Zacks reports. Two analysts have made estimates for Albany Molecular Research’s earnings. Albany Molecular Research reported earnings of $0.32 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 28.1%. The firm is scheduled to issue its next earnings results on Thursday, August 17th.

On average, analysts expect that Albany Molecular Research will report full-year earnings of $0.91 per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of $1.03 per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Albany Molecular Research.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. Albany Molecular Research had a positive return on equity of 4.64% and a negative net margin of 8.78%. The firm had revenue of $163.80 million during the quarter, compared to analyst estimates of $161.43 million. During the same quarter in the previous year, the firm earned $0.07 EPS. Albany Molecular Research’s quarterly revenue was up 55.1% compared to the same quarter last year.

A number of equities research analysts have commented on AMRI shares. Morgan Stanley cut Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price target for the company. in a research note on Thursday, May 11th. They noted that the move was a valuation call. William Blair reiterated an “outperform” rating on shares of Albany Molecular Research in a research note on Tuesday, May 23rd. First Analysis cut Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research note on Monday, June 12th. J P Morgan Chase & Co cut Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 8th. Finally, BidaskClub cut Albany Molecular Research from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Five research analysts have rated the stock with a hold rating, Albany Molecular Research presently has a consensus rating of “Hold” and a consensus price target of $18.00.

Shares of Albany Molecular Research (NASDAQ AMRI) traded up 0.05% during trading on Friday, reaching $21.76. The company’s stock had a trading volume of 629,856 shares. The stock’s market capitalization is $906.65 million. Albany Molecular Research has a 12-month low of $13.01 and a 12-month high of $22.17. The firm’s 50-day moving average is $21.70 and its 200-day moving average is $18.08.

COPYRIGHT VIOLATION WARNING: “Albany Molecular Research, Inc. (NASDAQ:AMRI) Expected to Announce Earnings of $0.23 Per Share” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/12/albany-molecular-research-inc-nasdaqamri-expected-to-announce-earnings-of-0-23-per-share.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu KCG Holdings LLC purchased a new position in shares of Albany Molecular Research during the second quarter valued at about $293,000. Parametric Portfolio Associates LLC boosted its position in shares of Albany Molecular Research by 24.5% in the second quarter. Parametric Portfolio Associates LLC now owns 36,527 shares of the biotechnology company’s stock valued at $793,000 after buying an additional 7,187 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Albany Molecular Research by 4.2% in the second quarter. California Public Employees Retirement System now owns 94,900 shares of the biotechnology company’s stock valued at $2,059,000 after buying an additional 3,800 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Albany Molecular Research by 18.3% in the second quarter. Vanguard Group Inc. now owns 1,561,105 shares of the biotechnology company’s stock valued at $33,875,000 after buying an additional 241,050 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Albany Molecular Research by 4.3% in the second quarter. Northern Trust Corp now owns 355,860 shares of the biotechnology company’s stock valued at $7,722,000 after buying an additional 14,765 shares during the last quarter. Hedge funds and other institutional investors own 73.43% of the company’s stock.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Get a free copy of the Zacks research report on Albany Molecular Research (AMRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply